Richard Bax, Sr. Partner TranScrip Partners Chairman of Superbugs & Superdrug
- Feb. 25, 2013 - CAMBRIDGE, U.K. --
READING UK, 25 FEB 2013 -- TranScrip Partners (http://www.transcrip-
is delighted to announce that Richard Bax (http://www.transcrip-
bax/) is the chairman of day one of Superbugs & Superdrugs a Focus on Antibacterials (http://www.smi-
superdrugs). This marks the 10th time Dr Bax will chair this meeting. Following his opening remarks, Dr Bax will present an update on current R&D and the regulatory environment covering topics such as big and little pharma activity and progress, a report on REACT, BSAC, IDSA, Barda FP7 EU and Innovative Medicines Initiative, a developer’s view on the EMA workshop on the development of new antibacterial medicines and prospects for the future.
This, the 15th Annual Superbugs and Superdrugs Conference, presented by SMi (http://www.smi-online.co.uk/pharmaceuticals
), will bring together industry leaders from contract organisations, pharma, biotechs, regulatory agencies and academia to discuss the latest developments in antibacterials and anti-infectives (http://www.transcrip-
Conference Chairman Richard Bax has over 100 publications in peer reviewed journals including the BMJ, The Lancet and the New England Journal of Medicine. His published articles cover topics such as clinical trials, antibiotic resistance and prescribing, PK/PD predictors of outcome and the pharmaceutical industry.---ENDS
TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. TranScrip Partners are strategic thinkers that do, and doers who think strategically.